Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Appl Microbiol Biotechnol ; 98(2): 603-10, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24158735

RESUMO

Phenazine natural products/compounds possess a range of biological activities, including anti-microbial and cytotoxic, making them valuable starting materials for drug development in several therapeutic areas. These compounds are biosynthesized almost exclusively by eubacteria of both terrestrial and marine origins from erythrose 4-phosphate and phosphoenol pyruvate via the shikimate pathway. In this paper, we report isolation of actinomycete bacteria from marine sediment collected in the Trondheimfjord, Norway. Screening of the isolates for biological activity produced several "hits", one of which was followed up by identification and purification of the active compound from the actinomycete bacterium Streptosporangium sp. The purified compound, identified as 1,6-dihydroxyphenazine-5,10-dioxide (iodinin), was subjected to extended tests for biological activity against bacteria, fungi and mammalian cells. In these tests, the iodinin demonstrated high anti-microbial and cytotoxic activity, and was particularly potent against leukaemia cell lines. This is the first report on the isolation of iodinin from a marine-derived Streptosporangium.


Assuntos
Actinomycetales/isolamento & purificação , Actinomycetales/metabolismo , Antibacterianos/isolamento & purificação , Antibacterianos/metabolismo , Sedimentos Geológicos/microbiologia , Actinomycetales/classificação , Actinomycetales/genética , Bactérias/efeitos dos fármacos , Linhagem Celular Tumoral , DNA Bacteriano/química , DNA Bacteriano/genética , DNA Ribossômico/química , DNA Ribossômico/genética , Estuários , Fungos/efeitos dos fármacos , Humanos , Dados de Sequência Molecular , Noruega , Fenazinas/isolamento & purificação , Fenazinas/metabolismo , RNA Ribossômico 16S/genética , Análise de Sequência de DNA
2.
Mar Drugs ; 11(2): 332-49, 2013 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-23364682

RESUMO

Despite recent improvement in therapy, acute myeloid leukemia (AML) is still associated with high lethality. In the presented study, we analyzed the bioactive compound iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from a marine actinomycetes bacterium for the ability to induce cell death in a range of cell types. Iodinin showed selective toxicity to AML and acute promyelocytic (APL) leukemia cells, with EC50 values for cell death up to 40 times lower for leukemia cells when compared with normal cells. Iodinin also successfully induced cell death in patient-derived leukemia cells or cell lines with features associated with poor prognostic such as FLT3 internal tandem duplications or mutated/deficient p53. The cell death had typical apoptotic morphology, and activation of apoptotic signaling proteins like caspase-3. Molecular modeling suggested that iodinin could intercalate between bases in the DNA in a way similar to the anti-cancer drug daunorubicin (DNR), causing DNA-strand breaks. Iodinin induced apoptosis in several therapy-resistant AML-patient blasts, but to a low degree in peripheral blood leukocytes, and in contrast to DNR, not in rat cardiomyoblasts. The low activity towards normal cell types that are usually affected by anti-leukemia therapy suggests that iodinin and related compounds represent promising structures in the development of anti-cancer therapy.


Assuntos
Actinobacteria/metabolismo , Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Leucemia Mieloide , Actinobacteria/química , Adolescente , Adulto , Animais , Antineoplásicos/química , Antineoplásicos/metabolismo , Linhagem Celular Tumoral , Daunorrubicina/química , Feminino , Regulação Bacteriana da Expressão Gênica/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Moleculares , Estrutura Molecular , Fenazinas/química , Fenazinas/metabolismo , Fenazinas/farmacologia , Ratos , Adulto Jovem
3.
J Sep Sci ; 34(23): 3359-63, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22086770

RESUMO

Bioprospecting aims at the identification of biological compounds with novel properties. Identification of such compounds in crude complex biological extracts is a comprehensive challenge. As a large number of extracts must be screened for successful identification of one potential promising lead, rational screening strategies must be developed. Here we report on a novel two stage rational LC-MS strategy of extracts already pre-screened and proven to contain bioactive compound(s). All extracts are initially fractionated using one and the same LC condition with parallel mass spectrometric detection. Fractions containing bioactive compound(s) are then subjected to a second fractional stage using two different chromatographic conditions. Mass detection is also included at this stage, and a cross-matching algorithm for comparison of processed mass chromatograms from the two dimensions was developed. The algorithm reports only masses present in bioactive fractions in both dimensions and enable therefore an efficient identification of potential masses that causes the bioactivity. This mass list can be used to search in natural compound database(s) for a rapid evaluation if the mass belongs to an already identified compound or if it is a potentially new one. This strategy enables thorough screening of several hundred crude extracts in one week on one single instrument.


Assuntos
Actinobacteria/química , Antifúngicos/química , Fatores Biológicos/química , Cromatografia Líquida de Alta Pressão/métodos , Espectrometria de Massas/métodos
5.
J Clin Psychopharmacol ; 29(3): 248-54, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19440078

RESUMO

The objective of this study was to characterize the usefulness and reliability of a commonly used urinary on-site drugs of abuse screening test device when used routinely at admittances to a psychiatric emergency unit. Urine samples from 262 emergency psychiatric admittances representing 217 patients were analyzed by a commercially available on-site test for the detection of amphetamines, benzodiazepines, cannabis, cocaine, and opiates in urine. The samples were first screened by nurses at the psychiatric department, thereafter by 2 technicians at the laboratory, and finally, analyzed by liquid chromatography/mass spectrometry. Results of 45.8% of the screening tests were true negative for all 5 drugs/drug groups tested, whereas those of 29.4% were true positive for 1 or several drugs/drug groups and true negative for the others. Thus, in total, 75.2% were correct for all 5 drugs/drug groups. In general, the sensitivities (42.9%-90.0% for the various drug groups) were lower than the specificities (92.7%-100.0%). The accuracies were 86.3% for benzodiazepines, 92.4% for cannabis, 94.7% for opiates, and 97.0% for amphetamines. No cocaine was found in any of the samples. For cannabis, the accuracy was higher among the laboratory technicians than among the nurses. The results from on-site screening testing should not be considered as the final conclusion on the intake of drugs of abuse but must be interpreted with caution.


Assuntos
Serviços de Emergência Psiquiátrica/métodos , Drogas Ilícitas/urina , Detecção do Abuso de Substâncias/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Cromatografia Líquida/métodos , Feminino , Humanos , Masculino , Espectrometria de Massas/métodos , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Urinálise/métodos , Adulto Jovem
6.
Tidsskr Nor Laegeforen ; 128(1): 42-5, 2008 Jan 03.
Artigo em Norueguês | MEDLINE | ID: mdl-18183057

RESUMO

BACKGROUND: In some situations, and particularly when intoxications are suspected, it would be advantageous if medicines and drugs of abuse could be swiftly detected in serum or urine. MATERIAL AND METHODS: The Department of Clinical Pharmacology at St. Olav University Hospital has since 2004 been developing a comprehensive toxicology service (at all hours 7-days/week) for immediate quantitative analysis of between 80 and 90 substances. We here present the service in further detail and evaluate its usefulness during its first full year, 2005. Two case reports are presented to further illustrate the possible benefits of this service. RESULTS: Urgent testing was requested for a total of 390 samples; 351 serum and 39 urine samples. The most common indications for requesting such analyses were suspected acute intoxication (46%) and suspected therapeutic failure/adverse drug reaction (31%). 88% of the serum samples obtained for acute intoxications were positive, and 48 different substances were detected. The substances most often found were various benzodiazepines, various antiepileptic drugs, ethanol, carisoprodol, lithium, and other psychotropic drugs. In urine, amphetamine and zopiclone were the substances most often detected. INTERPRETATION: The service seems to be used according to its intentions, and the high number of samples received indicate that clinicians consider the service to be useful. An early and continuous dialogue between the clinician and the laboratory physician is a prerequisite for rational use of the service.


Assuntos
Toxicologia Forense , Intoxicação/diagnóstico , Detecção do Abuso de Substâncias , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Adolescente , Adulto , Intoxicação Alcoólica/sangue , Intoxicação Alcoólica/diagnóstico , Intoxicação Alcoólica/urina , Anticonvulsivantes/sangue , Anticonvulsivantes/intoxicação , Anticonvulsivantes/urina , Benzodiazepinas/sangue , Benzodiazepinas/intoxicação , Benzodiazepinas/urina , Serviço Hospitalar de Emergência , Feminino , Toxicologia Forense/métodos , Toxicologia Forense/estatística & dados numéricos , Humanos , Intoxicação/sangue , Intoxicação/urina , Psicotrópicos/sangue , Psicotrópicos/intoxicação , Psicotrópicos/urina , Detecção do Abuso de Substâncias/métodos , Detecção do Abuso de Substâncias/estatística & dados numéricos , Transtornos Relacionados ao Uso de Substâncias/sangue , Transtornos Relacionados ao Uso de Substâncias/urina
8.
Toxicol Lett ; 166(1): 11-8, 2006 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-16793228

RESUMO

In heroin overdose deaths the blood morphine concentration varies substantially. To explore possible pharmacokinetic explanations for variable sensitivity to opiate toxicity we studied mortality and drug concentrations in male Sprague-Dawley rats. Groups of rats were injected intravenously (i.v.) with heroin, 21.5 mg/kg, or morphine, 223 mg/kg, causing a 60-80% mortality among drug-naïve rats. Additional groups of rats were pre-treated with morphine for 14 days, with or without 1 week of subsequent abstinence. Brain, lung and blood samples were analyzed for 6-acetylmorphine, morphine, morphine-3-glucuronide and morphine-6-glucuronide. i.v. morphine administration to drug-naïve rats resulted in both rapid and delayed deaths. The brain morphine concentration conformed to an exponential elimination curve in all samples, ruling out accumulation of morphine as an explanation for delayed deaths. This study found no support for formation of toxic concentration of morphine-6-glucuronide. Spontaneous death among both heroin and morphine rats occurred at fairly uniform brain morphine concentrations. Morphine pre-treatment significantly reduced mortality upon i.v. morphine injection, but the protective effect was less evident upon i.v. heroin challenge. The morphine pre-treatment still afforded some protection after 1 week of abstinence among rats receiving i.v. morphine, whereas rats given i.v. heroin showed similar death rate as drug-naïve rats.


Assuntos
Heroína/intoxicação , Morfina/intoxicação , Animais , Encéfalo/metabolismo , Modelos Animais de Doenças , Overdose de Drogas , Heroína/administração & dosagem , Heroína/sangue , Heroína/farmacocinética , Inativação Metabólica , Injeções Intraperitoneais , Injeções Intravenosas , Pulmão/metabolismo , Masculino , Morfina/administração & dosagem , Morfina/sangue , Morfina/farmacocinética , Ratos , Ratos Sprague-Dawley
9.
Am J Physiol Gastrointest Liver Physiol ; 289(6): G1052-60, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16099866

RESUMO

The lipid-lowering drug ciprofibrate stimulates gastrin-producing cells in the rat stomach without lowering gastric acidity. Although suggested to be a luminal action on antral peroxisome proliferator-activated receptor-alpha (PPAR-alpha), the mechanism is still not fully elucidated. Gastric bypass was surgically prepared in male Sprague-Dawley rats. Gastric-bypassed and sham-operated rats were either given ciprofibrate (50 mg.kg(-1).day(-1) in methocel) or vehicle alone for 7 wk. PPAR-alpha knockout (KO) and wild-type (WT) mice were either given ciprofibrate (500 mg.kg(-1).day(-1) in methocel) or vehicle alone for 2 wk. The concentration of gastrin in blood was analyzed. Antral G cell density and gastrin mRNA abundance were determined by using immunostaining and Northern blot analysis. Ciprofibrate did not raise plasma gastrin or G cell density in gastric-bypassed rats, although the gastrin mRNA level was slightly increased. In contrast, ciprofibrate induced hypergastrinemia, a 50% increase in G cell density, and a threefold increase in gastrin mRNA in sham-operated rats. In PPAR-alpha KO mice, ciprofibrate did not raise G cell density or the gastrin mRNA level. The serum gastrin level was reduced by ciprofibrate. In WT mice, ciprofibrate induced hypergastrinemia, a doubling of G cell density, and a threefold increase in gastrin mRNA. Comparing animals dosed with vehicle only, PPAR-alpha KO mice had higher serum gastrin concentration than WT mice. We conclude that the main effects of ciprofibrate on G cells are mediated from the antrum lumen, and the mechanism is dependent on PPAR-alpha. The results indicate that PPAR-alpha may have a role in the physiological regulation of gastrin release.


Assuntos
Ácido Clofíbrico/análogos & derivados , Células Secretoras de Gastrina/efeitos dos fármacos , Gastrinas/metabolismo , PPAR alfa/fisiologia , Antro Pilórico/efeitos dos fármacos , Animais , Ácido Clofíbrico/sangue , Ácido Clofíbrico/farmacologia , Feminino , Ácidos Fíbricos , Derivação Gástrica , Fígado/anatomia & histologia , Fígado/efeitos dos fármacos , Masculino , Camundongos , Camundongos Knockout , Tamanho do Órgão , PPAR alfa/agonistas , PPAR alfa/deficiência , Antro Pilórico/fisiologia , Ratos , Ratos Sprague-Dawley , Somatostatina/biossíntese
11.
Psychopharmacology (Berl) ; 176(3-4): 426-34, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15549277

RESUMO

RATIONALE: The active placebo hypothesis states that placebo effects are potentiated when an active drug is administered. OBJECTIVE: This hypothesis was tested in an experiment where information about the effect of a drug was combined with administration of an active drug or placebo. METHODS: Information that a drug acted as a relaxant, a stimulant, or as a placebo was crossed with oral administration of a relaxant drug (700 mg carisoprodol), a stimulant drug (400 mg caffeine) or placebo (lactose) in healthy volunteers ( n=94). Dependent variables were subjective and physiological measures of arousal, as well as serum carisoprodol and caffeine levels. Data were collected from 15 to 280 min after administration of drug or placebo. RESULTS: Caffeine increased alertness, systolic and diastolic blood pressure, startle blink reflexes, and skin conductance responses. Subjects were calmer after carisoprodol, and heart rate was increased. There was a positive correlation between increased arousal and carisoprodol levels when stimulant information had been provided. However, this was only seen when carisoprodol levels were very low. There was no evidence that caffeine modulated the placebo response. CONCLUSIONS: Active placebo responses were seen only transiently when carisoprodol levels were low, and only in the subjective arousal data. Caffeine did not support active placebo responses. The overall findings did not favour the active placebo hypothesis.


Assuntos
Estimulantes do Sistema Nervoso Central/farmacologia , Relaxantes Musculares Centrais/farmacologia , Adulto , Nível de Alerta/efeitos dos fármacos , Piscadela/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Cafeína/sangue , Cafeína/farmacologia , Carisoprodol/sangue , Carisoprodol/farmacologia , Catecolaminas/sangue , Estimulantes do Sistema Nervoso Central/sangue , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Eletromiografia , Feminino , Resposta Galvânica da Pele/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Humanos , Masculino , Meprobamato/sangue , Meprobamato/farmacologia , Relaxantes Musculares Centrais/sangue , Efeito Placebo , Reflexo/efeitos dos fármacos , Reflexo de Sobressalto/efeitos dos fármacos
12.
BMC Clin Pharmacol ; 4: 7, 2004 Oct 04.
Artigo em Inglês | MEDLINE | ID: mdl-15461818

RESUMO

BACKGROUND: The feasibility of drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. One important factor relevant to drug monitoring is to what extent morphine, M6G and M3G serum concentrations fluctuate during stable morphine treatment. METHODS: We included twenty-nine patients admitted to a palliative care unit receiving oral morphine (n = 19) or continuous subcutaneous (sc) morphine infusions (n = 10). Serum concentrations of morphine, M6G and M3G were obtained at the same time on four consecutive days. If readmitted, the patients were followed for another trial period. Day-to-day variations in serum concentrations and ratios were determined by estimating the percent coefficient of variation (CV = (mean/SD) x100). RESULTS: The patients' median morphine doses were 90 (range; 20-1460) mg/24 h and 135 (range; 30-440) mg/24 h during oral and sc administration, respectively. Intraindividual fluctuations of serum concentrations estimated by median coefficients of day-to-day variation were in the oral group for morphine 46%, for M6G 25% and for M3G 18%. The median coefficients of variation were lower in patients receiving continuous sc morphine infusions (morphine 10%, M6G 13%, M3G 9%). CONCLUSION: These findings indicate that serum concentrations of morphine and morphine metabolites fluctuate. The fluctuations found in our study are not explained by changes in morphine doses, administration of other drugs or by time for collection of blood samples. As expected the day-to-day variation was lower in patients receiving continuous sc morphine infusions compared with patients receiving oral morphine.


Assuntos
Analgésicos Opioides/sangue , Derivados da Morfina/sangue , Morfina/sangue , Neoplasias/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Cuidados Paliativos , Estudos Prospectivos
13.
J Clin Psychiatry ; 65(9): 1228-34, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15367050

RESUMO

BACKGROUND: The aims of the study were to quantify the drug exposure in breastfed infants of antidepressant-treated mothers, to identify possible adverse events, and to correlate these variables to maternal and infant drug metabolism-relevant genotypes and milk triglyceride content. METHOD: The study included 25 lactating women treated with citalopram (N = 9), sertraline (N = 6), paroxetine (N = 6), fluoxetine (N = 1), or venlafaxine (N = 3) and their 26 breastfed infants. Drug concentrations in maternal and infant serum and milk were analyzed using liquid chromotography mass spectrometry methods; milk triglyceride levels were measured with a commercial kit. Cytochrome P450 (CYP) 2D6 and CYP2C19 activity was determined by polymerase chain reaction-based genotyping of the mothers and infants. An infant adverse event questionnaire was completed by the medication-treated mothers as well as by a control group of medication-free breastfeeding mothers of 68 infants. RESULTS: Sertraline and paroxetine were not detected in any of the drug-exposed infants. The infant serum level of citalopram was either undetectable (N = 4) or low (N = 6). All venlafaxine-exposed infants had measurable drug concentrations. We identified a paroxetine-treated mother and her infant who were both CYP2D6 poor metabolizers, as well as a citalopram-treated mother with CYP2C19 poor metabolizer status, but the serum drug levels of their infants were still either undetectable (paroxetine) or low (citalopram). There was no evidence of adverse events in the drug-exposed infants. CONCLUSION: Serum drug levels in breastfed infants of antidepressant-treated mothers were undetectable or low. This study adds further evidence to previously published data indicating that breastfeeding should not be generally discouraged in women using serotonin reuptake inhibitor anti-depressants.


Assuntos
Aleitamento Materno , Sistema Enzimático do Citocromo P-450/genética , Depressão Pós-Parto/tratamento farmacológico , Lactação/sangue , Leite Humano/química , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Triglicerídeos/análise , Adulto , Hidrocarboneto de Aril Hidroxilases/genética , Hidrocarboneto de Aril Hidroxilases/metabolismo , Citocromo P-450 CYP2C19 , Citocromo P-450 CYP2D6/genética , Citocromo P-450 CYP2D6/metabolismo , Sistema Enzimático do Citocromo P-450/metabolismo , Depressão Pós-Parto/sangue , Depressão Pós-Parto/metabolismo , Feminino , Genótipo , Humanos , Lactente , Recém-Nascido , Lactação/genética , Lactação/metabolismo , Masculino , Exposição Materna/efeitos adversos , Leite Humano/metabolismo , Oxigenases de Função Mista/genética , Oxigenases de Função Mista/metabolismo , Paroxetina/análise , Paroxetina/metabolismo , Paroxetina/uso terapêutico , Farmacogenética , Fenótipo , Gravidez , Inibidores Seletivos de Recaptação de Serotonina/análise , Inibidores Seletivos de Recaptação de Serotonina/metabolismo , Sertralina/análise , Sertralina/metabolismo , Sertralina/uso terapêutico , Triglicerídeos/metabolismo
14.
Palliat Med ; 17(8): 679-87, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14694919

RESUMO

The clinical importance of routine drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. We measured morphine, M6G and M3G serum concentrations in cancer pain patients receiving oral (n = 263, median dose 80 mg/24 hours) or subcutaneous (sc) (n = 35, median dose 110 mg/24 hours) morphine. Regression analyses were performed to investigate if serum concentrations of morphine, M3G and M6G predicted pain intensity (Brief Pain Inventory), health-related quality-of-life variables (EORTC QLQ-C30) and cognitive function (Mini-Mental Score). Serum concentrations were also compared in patients categorized as morphine 'treatment successes' and 'treatment failures'. We observed that serum concentrations of morphine, M6G or M3G did not predict pain intensity, cognitive function, nausea or tiredness. 'Treatment failures' caused by nausea, tiredness, cognitive failure or constipation did not have statistically significant different morphine, M6G and M3G serum concentrations than patients classified as 'treatment successes'. In conclusion, this study did not observe any concentration-effect relationships of morphine, M3G or M6G with pain intensity, nausea, constipation, tiredness or cognitive failure in blood samples obtained during routine clinical drug monitoring in cancer patients. This result suggests that therapeutic drug monitoring as a routine tool during chronic morphine treatment has limited value for clinical decision making.


Assuntos
Analgésicos Opioides/administração & dosagem , Morfina/administração & dosagem , Dor/prevenção & controle , Administração Oral , Adulto , Idoso , Idoso de 80 Anos ou mais , Analgésicos Opioides/sangue , Transtornos Cognitivos/induzido quimicamente , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos , Fadiga/induzido quimicamente , Feminino , Humanos , Infusões Parenterais , Masculino , Pessoa de Meia-Idade , Morfina/sangue , Derivados da Morfina/sangue , Náusea/induzido quimicamente , Neoplasias/sangue , Neoplasias/complicações , Dor/sangue , Medição da Dor , Cuidados Paliativos
15.
Eur J Clin Pharmacol ; 58(5): 353-6, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12185559

RESUMO

OBJECTIVE: UDP-glucuronosyltransferase (UGT) 2B7 is the major UGT isoform responsible for the 3- and 6-glucuronidation of morphine in humans. Studies in rats have indicated that UGT1A1 may also contribute to the formation of morphine 3-glucuronide (M3G). Our objective was to investigate whether the UGT2B7 H268Y and UGT1A1*28 polymorphisms contribute to the variability in morphine glucuronide-to-morphine plasma ratios among cancer patients undergoing analgesic therapy with morphine. METHODS: Seventy patients with normal hepatic and renal function using slow-release morphine to relieve cancer pain were included. UGT2B7 genotyping was performed using restriction enzyme analysis of polymerase chain reaction (PCR)-amplified DNA fragments. Wild-type and variant alleles of the UGT1A1 gene were identified using sizing of PCR-amplified fragments. Morphine 6-glucuronide (M6G)/morphine, M3G/morphine, and M3G/M6G plasma ratios were compared between genotypes. RESULTS: The M3G/morphine, M6G/morphine, and M3G/M6G plasma ratios varied 16-, 42-, and sevenfold, respectively, among individuals. No statistically significant differences in plasma ratios were found between individuals possessing UGT2B7 H/H ( n=20), H/Y ( n=30), or Y/Y ( n=20) genotypes. Five patients were homozygous for the UGT1A1 TA(7) allele, which is associated with reduced UGT1A1 gene expression. However, the mean M3G/M6G and M3G/morphine plasma ratios in TA(7) homozygous subjects did not differ significantly from those of heterozygous or homozygous wild-type (TA(6)) individuals. CONCLUSION: The UGT2B7 H268Y polymorphism cannot account for the considerable variation in glucuronide-to-morphine ratios in cancer patients. Moreover, the contribution of UGT1A1 to the formation of M3G appears to be of minor biological significance, at least in a UGT2B7 background.


Assuntos
Analgésicos Opioides/sangue , Glucuronosiltransferase/genética , Derivados da Morfina/sangue , Morfina/sangue , Neoplasias/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/uso terapêutico , Genótipo , Humanos , Isoenzimas/genética , Pessoa de Meia-Idade , Morfina/administração & dosagem , Morfina/uso terapêutico , Neoplasias/fisiopatologia , Dor/tratamento farmacológico , Reação em Cadeia da Polimerase Via Transcriptase Reversa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA